Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eyetech Pharmaceuticals, Gilead deal

EyeTech received exclusive worldwide rights to GILD's aptamer

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE